United States Digital Therapeutics for Neurological Disorders Market is to reach USD 103.32 billion by 2034 | Major Players- Akili, Inc., Click Therapeutics, Inc., BigHealth, Apple Inc. | DataM Intelligence

Global Digital Therapeutics for Neurological Disorders Market reached US$ 246.94 million in 2024 and is expected to reach US$ 504.36 million by 2033, growing at a CAGR of 8.3% during the forecast period 2025-2033.

Download Free sample report:-https://www.datamintelligence.com/download-sample/digital-therapeutics-for-neurological-disorders-market?pratik

Recent Industry Development in U.S market:

✅ United States: Estimated at USD 16.31 billion in 2025, projected to reach around USD 103.32 billion by 2034, growing at a CAGR of 22.73%

✅ In April 2025, Click Therapeutics received FDA marketing authorization for CT‐132, the first prescription digital therapeutic for preventive treatment of episodic migraine in adults, to be used adjunctively.

✅ In August 2024, Otsuka Precision Health and Click Therapeutics launched Rejoyn, a prescription digital therapeutic cleared by FDA for major depressive disorder (MDD) (adjunctive use, age 22+), focused on cognitive control of emotion.

✅ In May 2025, Relief Therapeutics announced a binding merger with NeuroX Group (CHF 1 b deal). NeuroX had acquired MindMaze's digital neurotherapeutics assets; the combined entity aims to build an AI-driven neurotherapeutics platform for disorders like stroke, Parkinson's, and dementia.

✅ Also in May 2025, Nerva completed acquisition of key assets from Mahana Therapeutics, strengthening brain-gut behavioral therapy offerings, overlapping with neuro-behavioral health.

✅ In September 2024, Otsuka Pharmaceutical acquired Jnana Therapeutics (USD 800 million upfront + milestones) - Jnana's RAPID platform targets hard-to-drug neuroscience targets, thereby expanding digital therapeutic possibilities in neurological diseases.

Recent Industry Development in Japan market:

✅ In February 2025, Shionogi obtained domestic manufacturing & marketing approval in Japan for the digital therapeutic app ENDEAVORRIDE (SDT‐001) (originally Akili's EndeavorRx), for pediatric ADHD (adjunct therapy).

✅ In February 2024, Shionogi submitted marketing approval in Japan for SDT‐001 (localized version of AKL‐T01 / EndeavorRx) after encouraging Phase 3 results in children aged 6‐17 with ADHD.

✅ From a regulatory / policy perspective, Japanese analyses note increasing collaboration between drug companies and digital-health firms: for example, partnerships involving Akili Interactive and Shionogi for cognitive/neuro-digital therapies.

Key Investment

➠ Cognito Therapeutics (U.S.): Raised US$ 73 million in a Series B round (March 2023) led by FoundersX Ventures, with participation from Alzheimer's Drug Discovery Foundation (ADDF), Starbloom Capital, IAG Capital, and WS Investment.

➠ MindMaze (Switzerland / U.S.): Secured US$ 125 million in investment from AlbaCore Capital Group (October 2021) to scale its digital neurotherapeutics platform.

➠ Biogen & MedRhythms (U.S.): Biogen entered a licensing/collaboration deal with MedRhythms to develop a prescription digital therapeutic (MR-004) for gait deficits in multiple sclerosis.

➠ MedRhythms received US$ 3 million upfront, and is eligible for up to US$ 117.5 million in milestone payments, plus tiered royalties on global sales.

➠ Supernus Pharmaceuticals (U.S.) / Sage Therapeutics: In June 2025, Supernus agreed to acquire Sage Therapeutics for US$ 561 million upfront, potentially rising to US$ 795 million with milestones.

➠ Draig Therapeutics (U.K.): Raised US$ 140 million in a Series A round (June 2025) to advance its oral compound DT-101 targeting severe depression and other neurological disorders.

Benefits of AI for the Digital Therapeutics for Neurological Disorders Market

➠Personalized treatment plans using AI algorithms to tailor therapies to individual patient needs.

➠Predictive analytics to identify early signs of disease progression and recommend interventions.

➠Enhanced patient engagement through AI-driven apps and interactive digital platforms.

➠Remote monitoring of patient symptoms and adherence using AI-powered sensors and wearables.

➠Data-driven insights to optimize therapy effectiveness and adjust protocols in real-time.

➠Automation of routine assessments, reducing clinician workload and improving accuracy.

➠AI-assisted cognitive and motor function exercises for improved neurological outcomes.

➠Early detection of adverse effects or complications using AI pattern recognition.

"Secure your 30% year-end discount - get this report before the offer expires."
:https://www.datamintelligence.com/buy-now-page?report=digital-therapeutics-for-neurological-disorders-market?pratik ((Purchase 2 or more Repots and get 50% Discount)

Segmentation Analysis :

By Product Type:

➠The market is broadly divided into software therapeutics and wearable devices.

➠Software therapeutics dominate: these include mobile apps, web-based platforms, and cloud-based software, favored for their flexibility, scalability, and ease of access for patients.

➠Wearable devices (e.g., sensors, neuro‐monitoring wearables) complement software by providing real-time, continuous physiological and behavioral monitoring.

By Disease Type:

➠The market is segmented by different neurological disorders:

➠Neurodegenerative Disorders ( Alzheimer's, Parkinson's)

➠Mental Health / Behavioral Disorders (depression, anxiety)

➠Stroke & Cerebrovascular Disorders

➠Sleep Disorders

➠Cognitive Disorders ( cognitive decline, memory impairment)

➠Others - less common or emerging neurological use‐cases.

By End‐User:

➠These are the main groups that consume or deploy digital therapeutics in the neurological space:

➠Hospitals - large healthcare systems use digital therapeutics as part of integrated treatment.

➠Specialty Clinics / Neurology Centers - focused neurology clinics adopt advanced DTx tools for specific neurological conditions.

➠Neuro‐rehabilitation Centers - centers that provide rehab (motor, cognitive) rely on digital interventions.

➠Homecare Settings - a key and growing segment: patients using DTx from their homes (remote monitoring, self‐management).

➠Others - potentially includes academic/research institutions, payers, or care providers depending on reports.

Regional Insights:

➠ North America: Dominant region 37- 40% of global market in 2023-2024. Growth is driven by advanced healthcare infrastructure, strong digital health adoption, favorable regulatory frameworks (FDA), high R&D investment, and well-established reimbursement pathways.

➠ Asia‐Pacific: Fastest‐growing region. According to Future Market Insights, APAC shows very high growth potential, particularly in China, India, Japan, and South Korea. Credence Research also projects around 20-23% of global share for APAC, driven by rising healthcare digitization, large patient pool, government initiatives, and increasing smartphone / wearable penetration.

➠ Europe: Mature and stable region, with approximately 25-30% share in some analyses. Growth is more moderate; driven by supportive but fragmented regulatory frameworks increasing digital health funding, and strong public health systems pushing for cost-efficient neurotherapeutic solutions.

Growth drivers:

Rising global prevalence of neurological disorders (Alzheimer's, Parkinson's, epilepsy).

Aging population increasing patient pool.

Advances in AI, machine learning, and wearable sensor technologies.

Growing demand for personalized, non-drug treatment options.

Increasing adoption of telehealth and remote patient monitoring.

Favorable regulatory support and increasing reimbursement coverage.

Focus on cost-effective, evidence-based digital interventions.

Integration with electronic health records for comprehensive management.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/digital-therapeutics-for-neurological-disorders-market?pratik

Key players:

Akili, Inc., Click Therapeutics, Inc., BigHealth, Apple Inc., MindMaze Inc, NeuroPace, Inc., NeurologyToolKit, Matoph Labs e.U., Fullpower Technologies, Inc., Neybox Digital Ltd.

Key highlights:

➠ Akili, Inc.
Pioneering digital therapies targeting cognitive disorders like ADHD and Alzheimer's. Known for FDA-cleared prescription digital therapeutics, contributing significantly to North American and European markets.

➠ Click Therapeutics, Inc.
Focuses on software-based interventions for neurological and psychiatric disorders. Strong emphasis on clinical validation and regulatory approvals strengthens its presence in U.S. and EU markets.

➠ BigHealth
Specializes in digital sleep and mental wellness programs. Their evidence-based, app-delivered cognitive behavioral therapies (CBT) drive adoption in North America and expanding markets in Europe and Asia-Pacific.

➠ Apple Inc.
Leveraging wearable technology and integrated health platforms to monitor neurological health. Their ecosystem supports scalable digital interventions, positioning them as a key player in consumer-driven therapeutic solutions.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?pratik

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insightsthrough pricing analysis, market share breakdowns, and competitive intelligence. Thecompany specializes in strategic reports that guide businesses in high-growth sectors suchas nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter,LinkedIn and Facebook.

This release was published on openPR.